EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

Franco Locatelli iD, Michelle L Schoettler iD, David Bueno-Sánchez iD, Sonali Chaudhury, Jude Fry, Eric Bachman, Min Qin, Cynthia Carrillo-Infante, Cory Williams, Aviva Krauss, Sarah Lawson iD, Yoshiyuki Takahashi iD und 4 weitere

American Journal of Hematology · 13.11.2026

DOI: 10.1002/ajh.70545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 13.11.2026. Verfasst von Franco Locatelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital and Catholic Un…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic stem cell transplantation‐associated thrombotic microangiopathy (HSCT‐TMA) is a rare, life‐threatening complication that can lead to multiorgan failure and death. The ALXN1210‐TMA‐314 global, Phase 3, open‐label, single‐arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT‐TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT‐TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight‐based ravulizumab plus best supportive care during the 26‐week treatment period, followed by a 26‐week follow‐up period. The protocol‐defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT‐TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. Trial Registration NCT04557735

Schlagwörter

Stichwörter der Autor:innen

clinical trialhematopoietic stem cell transplantationpediatric patientsravulizumabthrombotic microangiopathy

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital and Catholic University of the Sacred Heart, Rome, Italy.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.
  • Pediatric Hematology and Oncology Department, La Paz University Hospital, Madrid, Spain.
  • Stem Cell Transplantation and Cellular Therapies, Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Alexion, AstraZeneca Rare Disease, Baar, Switzerland.
  • Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.

ORCID-Profile: Franco Locatelli, Michelle L Schoettler, David Bueno-Sánchez, Sarah Lawson, Yoshiyuki Takahashi, Hideki Sano, Daiichirou Hasegawa, Hyoung Jin Kang, Christopher C Dvorak

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Locatelli, F., Schoettler, M. L., Bueno-Sánchez, D., Chaudhury, S., Fry, J., Bachman, E., Qin, M., Carrillo-Infante, C., Williams, C., Krauss, A., Lawson, S., Takahashi, Y., Sano, H., Hasegawa, D., Kang, H. J., & Dvorak, C. C. (2026). Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial. American Journal of Hematology. https://doi.org/10.1002/ajh.70545

Vancouver

Locatelli F, Schoettler ML, Bueno-Sánchez D, Chaudhury S, Fry J, Bachman E, et al. Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial. American Journal of Hematology. 2026. doi:10.1002/ajh.70545

BibTeX
@article{Locatelli2026,
  author = {Locatelli, Franco and Schoettler, Michelle L and Bueno-Sánchez, David and Chaudhury, Sonali and Fry, Jude and Bachman, Eric and Qin, Min and Carrillo-Infante, Cynthia and Williams, Cory and Krauss, Aviva and Lawson, Sarah and Takahashi, Yoshiyuki and Sano, Hideki and Hasegawa, Daiichirou and Kang, Hyoung Jin and Dvorak, Christopher C},
  title = {Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70545}
}
Kostenlos starten →